Press Releases

27/11/2019 OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3

11/11/2019 OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®

07/11/2019 OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea

30/09/2019 OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor

18/09/2019 OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance

05/09/2019 OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update

03/09/2019 OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703

23/07/2019 OSE Immunotherapeutics Receives a Grant from the French National Research Agency

17/07/2019 First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance

10/07/2019 OSE Immunotherapeutics Receives Special Recognition for European Growth

26/06/2019 OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting

24/06/2019 OSE Immunotherapeutics will participate in HealthTech Investor Days

20/06/2019 Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC

17/06/2019 Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient

11/06/2019 OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Use of Tedopi® to Treat Brain Metastasis

28/05/2019 OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum

22/05/2019 OSE Immunotherapeutics to Host Key Opinion Leader Meeting

20/05/2019 OSE Immunotherapeutics Receives Notice of Allowance for New U.S. Patent Protecting OSE-127

1 2 3 4 5 6 7 8 9 10 11 12